Taddei Stefano, Caraccio Nadia, Virdis Agostino, Dardano Angela, Versari Daniele, Ghiadoni Lorenzo, Salvetti Antonio, Ferrannini Ele, Monzani Fabio
Department of Internal Medicine, University of Pisa, 56100 Pisa, Italy.
J Clin Endocrinol Metab. 2003 Aug;88(8):3731-7. doi: 10.1210/jc.2003-030039.
Subclinical hypothyroidism (sHT) is associated with enhanced cardiovascular risk. To test the hypothesis that patients with sHT are characterized by endothelial dysfunction and impaired nitric oxide (NO) availability, in 14 patients [serum cholesterol, 218 +/- 41 mg/dl (5.6 +/- 0.9 mM)] and 28 euthyroid subjects, subdivided into groups A and B [serum cholesterol, 170 +/- 19 mg/dl (4.4 +/- 0.5 mM) and 217 +/- 21 mg/dl (5.6 +/- 0.5 mM), respectively], we studied the forearm blood flow (strain-gauge plethysmography) response to intrabrachial acetylcholine, an endothelium-dependent vasodilator, at baseline and during infusion of N(G)-monomethyl-L-arginine (L-NMMA), a NO synthase inhibitor. Response to sodium nitroprusside and minimal forearm vascular resistances were also evaluated. In sHT patients, vasodilation to acetylcholine was reduced, compared with group B (+358 +/- 29% vs. +503 +/- 19%, P = 0.0003) and group A (663 +/- 65%, P = 0.02 vs. group B and P = 0.0002 vs. sHT). L-NMMA blunted the vasodilation to acetylcholine in groups A and B (49.1 +/- 6.3% and 42.7 +/- 5.5% maximal forearm blood flow reduction, respectively, P < 0.0001 vs. acetylcholine), whereas it was ineffective in sHT patients (12.8 +/- 2.5%). Response to sodium nitroprusside and minimal vascular resistances were similar. In sHT (n = 9) patients, 6 months of euthyroidism by levothyroxine replacement increased acetylcholine-vasodilation and restored L-NMMA inhibition. Patients with sHT are characterized by endothelial dysfunction resulting from a reduction in NO availability, an alteration partially independent of dyslipidemia and reversed by levothyroxine supplementation.
亚临床甲状腺功能减退(sHT)与心血管风险增加有关。为了验证sHT患者具有内皮功能障碍和一氧化氮(NO)可用性受损这一假说,我们对14例患者[血清胆固醇,218±41mg/dl(5.6±0.9mM)]和28例甲状腺功能正常的受试者进行了研究,后者分为A组和B组[血清胆固醇分别为170±19mg/dl(4.4±0.5mM)和217±21mg/dl(5.6±0.5mM)],我们在基线时以及在输注NO合酶抑制剂N(G)-单甲基-L-精氨酸(L-NMMA)期间,研究了前臂血流(应变片体积描记法)对肱动脉内注入内皮依赖性血管扩张剂乙酰胆碱的反应。还评估了对硝普钠的反应和最小前臂血管阻力。与B组(+358±29%对+503±19%,P = 0.0003)和A组相比,sHT患者对乙酰胆碱的血管舒张作用降低(663±65%,与B组相比P = 0.02,与sHT组相比P = 0.0002)。L-NMMA减弱了A组和B组对乙酰胆碱的血管舒张作用(最大前臂血流减少分别为49.1±6.3%和42.7±5.5%),P<0.0001(与乙酰胆碱相比),而在sHT患者中无效(12.8±2.5%)。对硝普钠的反应和最小血管阻力相似。在9例sHT患者中,通过左甲状腺素替代治疗使甲状腺功能正常6个月,增加了乙酰胆碱介导的血管舒张作用并恢复了L-NMMA的抑制作用。sHT患者的特征是由于NO可用性降低导致内皮功能障碍,这种改变部分独立于血脂异常,并且通过补充左甲状腺素可以逆转。